首页> 美国卫生研究院文献>Advanced Science >Engineering of Nebulized Metal–Phenolic Capsules for Controlled Pulmonary Deposition
【2h】

Engineering of Nebulized Metal–Phenolic Capsules for Controlled Pulmonary Deposition

机译:雾化金属酚醛胶囊控制肺部沉积的工程

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Particle‐based pulmonary delivery has great potential for delivering inhalable therapeutics for local or systemic applications. The design of particles with enhanced aerodynamic properties can improve lung distribution and deposition, and hence the efficacy of encapsulated inhaled drugs. This study describes the nanoengineering and nebulization of metal–phenolic capsules as pulmonary carriers of small molecule drugs and macromolecular drugs in lung cell lines, a human lung model, and mice. Tuning the aerodynamic diameter by increasing the capsule shell thickness (from ≈100 to 200 nm in increments of ≈50 nm) through repeated film deposition on a sacrificial template allows precise control of capsule deposition in a human lung model, corresponding to a shift from the alveolar region to the bronchi as aerodynamic diameter increases. The capsules are biocompatible and biodegradable, as assessed following intratracheal administration in mice, showing >85% of the capsules in the lung after 20 h, but <4% remaining after 30 days without causing lung inflammation or toxicity. Single‐cell analysis from lung digests using mass cytometry shows association primarily with alveolar macrophages, with >90% of capsules remaining nonassociated with cells. The amenability to nebulization, capacity for loading, tunable aerodynamic properties, high biocompatibility, and biodegradability make these capsules attractive for controlled pulmonary delivery.
机译:基于颗粒的肺部输送具有为局部或全身应用输送可吸入治疗剂的巨大潜力。具有增强的空气动力学性质的颗粒的设计可以改善肺的分布和沉积,并因此改善封装的吸入药物的功效。这项研究描述了金属酚醛胶囊的纳米工程和雾化作用,它们是肺细胞系,人肺模型和小鼠中小分子药物和大分子药物的肺部载体。通过在牺牲模板上重复沉积膜,通过增加胶囊壳的厚度(从≈100到200 nm,以≈50nm的增量)来调整空气动力学直径,可以精确控制人肺模型中的胶囊沉积,这与从随着空气动力学直径的增加,到支气管的肺泡区域。如在小鼠气管内给药后评估,这些胶囊具有生物相容性和可生物降解性,显示20小时后肺中有> 85%的胶囊,但30天后剩余的<4%没有引起肺部炎症或毒性。使用大量细胞计数法从肺部消化物中进行单细胞分析显示,其主要与肺泡巨噬细胞相关,其中90%以上的胶囊与细胞无关。雾化的适应性,负载能力,可调节的空气动力学特性,高生物相容性和生物降解性使这些胶囊对受控的肺部输送具有吸引力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号